Hestia Moningka1,2, Sarah Lichenstein1, Sarah W Yip1. 1. Department of Psychiatry, Yale School of Medicine, New Haven, CT, 06510. 2. University College London, Division of Psychology and Language Sciences, London WC1H 0AP.
Abstract
PURPOSE OF REVIEW: This review provides an overview of the neurobiological mechanisms underlying opioid use disorder (OUD) drawing from genetic, functional and structural magnetic resonance imaging (MRI) research. RECENT FINDINGS: Preliminary evidence suggests an association between OUD and specific variants of the DRD2, δ-opioid receptor 1 (OPRD1) and μ-opioid receptor 1 (OPRM1) genes. Additionally, MRI research indicates functional and structural alterations in striatal and corticolimbic brain regions and pathways underlying reward, emotion/stress and cognitive control processes among individuals with OUD. SUMMARY: Individual differences in genetic and functional and structural brain-based features are correlated with differences in OUD severity and treatment outcomes, and therefore may potentially one day be used to inform OUD treatment selection. However, given the heterogeneous findings reported, further longitudinal research across different stages of opioid addiction is needed to yield a convergent characterization of OUD and improve treatment and prevention.
PURPOSE OF REVIEW: This review provides an overview of the neurobiological mechanisms underlying opioid use disorder (OUD) drawing from genetic, functional and structural magnetic resonance imaging (MRI) research. RECENT FINDINGS: Preliminary evidence suggests an association between OUD and specific variants of the DRD2, δ-opioid receptor 1 (OPRD1) and μ-opioid receptor 1 (OPRM1) genes. Additionally, MRI research indicates functional and structural alterations in striatal and corticolimbic brain regions and pathways underlying reward, emotion/stress and cognitive control processes among individuals with OUD. SUMMARY: Individual differences in genetic and functional and structural brain-based features are correlated with differences in OUD severity and treatment outcomes, and therefore may potentially one day be used to inform OUD treatment selection. However, given the heterogeneous findings reported, further longitudinal research across different stages of opioid addiction is needed to yield a convergent characterization of OUD and improve treatment and prevention.
Authors: Scott C Wollman; Omar M Alhassoon; Mark J Stern; Matthew G Hall; Joscelyn Rompogren; Christine L Kimmel; Adlyn M Perez-Figueroa Journal: Am J Drug Alcohol Abuse Date: 2015-02-09 Impact factor: 3.829
Authors: Nico U F Dosenbach; Damien A Fair; Alexander L Cohen; Bradley L Schlaggar; Steven E Petersen Journal: Trends Cogn Sci Date: 2008-02-11 Impact factor: 20.229
Authors: Zhenhao Shi; An-Li Wang; Kanchana Jagannathan; Victoria P Fairchild; Charles P O'Brien; Anna Rose Childress; Daniel D Langleben Journal: J Psychiatry Neurosci Date: 2018-07 Impact factor: 6.186
Authors: André Schmidt; Stefan Borgwardt; Hana Gerber; Gerhard A Wiesbeck; Otto Schmid; Anita Riecher-Rössler; Renata Smieskova; Undine E Lang; Marc Walter Journal: Biol Psychiatry Date: 2013-11-04 Impact factor: 13.382
Authors: Rachel L Kember; Rachel Vickers-Smith; Heng Xu; Sylvanus Toikumo; Maria Niarchou; Hang Zhou; Emily E Hartwell; Richard C Crist; Christopher T Rentsch; Lea K Davis; Amy C Justice; Sandra Sanchez-Roige; Kyle M Kampman; Joel Gelernter; Henry R Kranzler Journal: Nat Neurosci Date: 2022-09-28 Impact factor: 28.771
Authors: Patrick H Finan; Janelle Letzen; David H Epstein; Chung Jung Mun; Samuel Stull; William J Kowalczyk; Daniel Agage; Karran A Phillips; Diego A Pizzagalli; Kenzie L Preston Journal: Pain Med Date: 2021-09-08 Impact factor: 3.750